447 related articles for article (PubMed ID: 38111008)
21. Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex.
Vasta JD; Michaud A; Zimprich CA; Beck MT; Swiatnicki MR; Zegzouti H; Thomas MR; Wilkinson J; Crapster JA; Robers MB
Cell Chem Biol; 2023 Nov; 30(11):1354-1365.e6. PubMed ID: 37643616
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
Yen I; Shanahan F; Merchant M; Orr C; Hunsaker T; Durk M; La H; Zhang X; Martin SE; Lin E; Chan J; Yu Y; Amin D; Neve RM; Gustafson A; Venkatanarayan A; Foster SA; Rudolph J; Klijn C; Malek S
Cancer Cell; 2018 Oct; 34(4):611-625.e7. PubMed ID: 30300582
[TBL] [Abstract][Full Text] [Related]
23. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
25. CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
Noeparast A; Giron P; Noor A; Bahadur Shahi R; De Brakeleer S; Eggermont C; Vandenplas H; Boeckx B; Lambrechts D; De Grève J; Teugels E
Oncogene; 2019 Aug; 38(31):5933-5941. PubMed ID: 31285551
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
[TBL] [Abstract][Full Text] [Related]
27. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
28. Selective CRAF Inhibition Elicits Transactivation.
Morgan CW; Dale IL; Thomas AP; Hunt J; Chin JW
J Am Chem Soc; 2021 Mar; 143(12):4600-4606. PubMed ID: 33750116
[TBL] [Abstract][Full Text] [Related]
29. BRAF mutation and its inhibitors in sarcoma treatment.
Liu H; Nazmun N; Hassan S; Liu X; Yang J
Cancer Med; 2020 Jul; 9(14):4881-4896. PubMed ID: 32476297
[TBL] [Abstract][Full Text] [Related]
30. Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation.
Mitra S; Ghosh B; Gayen N; Roy J; Mandal AK
J Biol Chem; 2016 Nov; 291(47):24579-24593. PubMed ID: 27703006
[TBL] [Abstract][Full Text] [Related]
31. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
32. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
33. No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.
Kumagai A; Namba H; Takakura S; Inamasu E; Saenko VA; Ohtsuru A; Yamashita S
Endocr J; 2006 Oct; 53(5):615-20. PubMed ID: 16896265
[TBL] [Abstract][Full Text] [Related]
34. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
35. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
36. Raf kinases in cancer-roles and therapeutic opportunities.
Maurer G; Tarkowski B; Baccarini M
Oncogene; 2011 Aug; 30(32):3477-88. PubMed ID: 21577205
[TBL] [Abstract][Full Text] [Related]
37. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Sanclemente M; Francoz S; Esteban-Burgos L; Bousquet-Mur E; Djurec M; Lopez-Casas PP; Hidalgo M; Guerra C; Drosten M; Musteanu M; Barbacid M
Cancer Cell; 2018 Feb; 33(2):217-228.e4. PubMed ID: 29395869
[TBL] [Abstract][Full Text] [Related]
38. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
39. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
[TBL] [Abstract][Full Text] [Related]
40. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
